EXCLUSIVE: NurExone's Wholly-Owned Subsidiary Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NUREXONE BIOLOGIC INC

NUREXONE BIOLOGIC INC

NRXBF

0.00

The commercial terms outlined in the MOU, including territorial exclusivity, upfront exclusivity fees,
minimum purchase commitments, funded market-entry obligations, regulatory responsibilities, and
potential regional expansion rights, are intended to be incorporated into the Definitive Agreement, which
the parties intend to execute within forty-five (45) calendar days. If completed, the Definitive Agreement
will provide Exo-Top with its first structured commercial foothold for naïve MSC-derived exosome
products.